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Antibiotic-resistant bacteria are one of the most 
significant current threats to human health. The 
diminishing antibiotic development pipeline 
coupled with the propensity for bacterial patho-
gens to evolve resistance represents an ongoing 
crisis that needs to be addressed [1]. Resistance 
development has long been a major concern 
with Staphylococcus aureus, a notorious bacterial 
pathogen that causes a wide spectrum of acute 
and chronic disease. The incidence of methicil-
lin-resistantS. aureus (MRSA) infections in both 
hospital and community settings continues to 
rise [2], and healthcare-associated infections due 
to MRSA cost more and lead to longer hospital 
stays than those caused by any other bacterial 
pathogen [3]. Antibiotic stewardship to preserve 
the most efficacious treatments for severe bac-
terial infections needs to be at the forefront of 
strategies designed to address growing resistance 
challenges. How can these principles be applied 
to managing S. aureus disease burden? When 
considering the breadth of infections caused by 
S. aureus, the majority are skin and soft tissue 
infections (SSTis), resulting in 11.6 million 
ambulatory care visits per year [4]. In emergency 
departments, 76o/o of S. aureus cases are SSTis 
and 59o/o of these are MRSA [5]. Many of these 
SSTis would be considered uncomplicated and 
treated with straightforward courses of antibiot-
ics. Considering these points, the load of anti-
biotic therapy being directed toward S. aureus 
SSTis is significant, and it seems probable that 
this is contributing to resistance development. 
What if innovative countermeasures for SSTis 
that do not drive resistance could be translated 
into approved therapies? Such a strategy could 
help preserve the most effective antibiotics for 
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the severe, deep-seated S. aureus infections and 
enable uncomplicated infections to be treated 
more rapidly and effectively. 
Antivirulence strategies represent a promis-
ing approach that could address the challenge of 
antibiotic stewardship [1]. The concept underly-
ing antivirulence is to shut down pathogenesis 
mechanisms in the invading bacteria without 
impacting growth, thereby enabling the host 
immune system to clear the infection in the 
absence of antibiotics. Quorum-sensing systems 
in particular have drawn attention as targets 
for the development of virulence-controlling 
therapeutics [6]. Although bioactive agents that 
function in this manner have yet to reach the 
clinic, animal model studies suggest potential 
for the approach [7,8]. The strategy of disarm-
ing the pathogen could lead to treatments that 
do not select or enrich for bacterial resistance, 
while simultaneously preserving the beneficial 
resident flora. This article covers some of the 
recent advances in the discovery and develop-
ment of small-molecule antivirulence agents that 
inhibit S. aureus quorum sensing. 
Pathogenesis in S. aureus is regulated by the 
agr quorum-sensing system, a cell density-depen-
dent regulator that responds to the extracellular 
concentration of a peptide signaling molecule 
(reviewed in [9]). This signaling molecule is a 
modified peptide (called an auto inducing pep-
tide [AlP]), which is typically 7-9 residues in 
length and has its last five residues cyclized into 
a thiolactone ring. The AlP signal is produced 
from a ribosomal precursor and processed and 
secreted from the cell by the AgrB membrane 
endopeptidase and signal peptidase SpsB. Once 
AlP reaches a critical concentration, it binds to a 
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receptor on the AgrC histidine kinase, activating 
the kinase to phosphorylate the AgrA response 
regulator and inducing the quorum-sensing sys-
tem. The primary output of AgrA is a large tran-
script called RNAIII, driven by the P3 promoter, 
and high RNAIII levels lead to the production 
of numerous virulence factors, including toxins, 
elm-enzymes and immunomodulators. Small 
molecules that inhibit this system (referred to as 
'quorum quenchers') are the focus of this article, 
and three obvious targets for such compounds 
are AgrC, AgrA or AgrB. Of these, AgrC has 
been the subject of most research and develop-
ment, and its extracellular location and func-
tion as the AlP receptor have drawn considerable 
attention. However, AgrC exhibits signs ofbeing 
hypermutable [10], porentially meaning a future 
reservoir of resistance. By contrast, AgrA and 
AgrB are highly conserved among the Staphylo-
cocci and even other Gram-positive pathogens. 
Targeting these proteins could ultimately prove 
more fruitful. 
..... interfering autoinducing peptide 
structures have proven effective for 
treatment of Slophylococcus aureus skin 
abscess in mouse models, suggesting the 
potential benefit of quorum quenching 
to prevent skin and soft ttssue Infections." 
The lim identified quorum-quenching agents 
are the AlPs themselves, which are produced by 
S. aur~ and other Staphylococcal strains, and 
interact directly with AgrC. Through a mecha-
nism coined 'at;r interference', the AIPs pro-
duced by one strain can cross-inhibit a strain 
producing a different agr class [9]. This property 
of the agr system has led to the identification 
of peptide scaffolds that act as AgrC-receptor 
antagonists and inhibit specific S. au reus strains. 
Such interfering AIP structures have proven 
effective for treatment of S. aur~ skin abscess 
in mouse models [1], suggesting the potential 
benefit of quorum quenching to prevent SSTI. 
Development of AlP-based receptor antagonists 
continues to be an active area of exploration, 
and numerous inhibiting structures have been 
identified and optimized (recently reviewed 
[s]). Chemical screening has also identified syn-
thetic agents thought to act as AgrC-receptor 
antagonists, such as benzbromarone, a treatment 
for gout. Benzbromarone is a potent quorum 
quencher (IC;0: 0.1-0.2 p.M) and inhibits pro-
duction of .:tgr-regulated virulence facton in all 
types of S. aur~ strains [B]. 
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The output of AgrC is the phosphorylation of 
the AgrA response regulator and, in turn, the up-
regulation of RNAIII to induce S. aur~ viru-
lence. Identification of agents that target ArgA 
directly or prevent the induction of RNAIII 
has yielded promising leads. The DNA-binding 
domain structure of the AgrA response regula-
tor has been solved, and this structure has been 
used as a template for nuclear magnetic reso-
nance-based inhibitor screening [11]. The best 
AgrA inhibitors were confirmed in electropho-
retic mobility shift assays using purified protein. 
Computer docking has also yielded promising 
AgrA small-molecule inhibitors, which were 
verified in follow-up studies [12]. Using RNAIII 
production as an output, the synthetic small-
molecule quorum qucncher named savirin, for 
S. aur~ virulence inhibitor, was identified by 
combinatorial library screening [13]. Savirin is a 
potent inhibitor ofRNAIII transcription (IC
50
: 
-1 p.M) and simultaneously prevents the pro-
duction of virulence factors a-toxin and phenol 
soluble modulins. Most importantly, savirin 
attenuated MRSA in a mouse model ofSSTI and 
showed no potential for resistance development 
through successive rounds of in vivo testing [13]. 
Another strategy of quorum quenching that 
has yielded preliminary success is targeting the 
production of the AlP signal. The Type I signal 
peptidase SpsB is essential for AlP biosynthesis, 
and linear peptide inhibitors of this peptidase 
were found to quench the agr system across 
strains [14]. The fungal metabolite ambuic acid 
was identified in screens for compounds that 
inhibited the production of the peptide quo-
rum-sensing signal in Enterococcus fo«mis [15]. In 
follow-up analysis, ambuic acid successfully pre-
vented endopeptidase activity in the AgrB homo-
log FsrB, and it acted as a quorum quencher by 
inhibiting AlP production in S. aur~ and other 
Gram positives [15]. 
"The concept of screening based on 
quorum quenching activity is relatively 
new to the natural products community; 
nonetheless. some promising findings 
have recently been published." 
Natural products have proven to be a rich 
source of anti-infective agents, with approxi-
mately 77% of drugs for this purpose derived 
from natural sources [16]. The concept of 
screening based on quorum quenching activity 
is relatively new to the natural products com-
munity; nonetheless, some promising findings 
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have recently been published. One example is 
the previously mentioned AgrB inhibitor ambuic 
acid, which is a polyketide-derivc:d epoxyqui-
none produced by fungi of Monochaetia spp. and 
Pestalotiopsis spp [15]. Other examples include 
cyclized dipeptide molecules secreted by Lac-
tobaciUus reuteri, which are thought to inhibit 
AgrC-A two-component action [17], and the 
compound norlichexanthone, which is produced 
by the fungus PeniciUium a/git/um [18]. Botanical 
extracts and their components have also been 
shown to possess quorum quenching activity 
against S. aureus. In one study, multiple plant 
extracts were found to inhibit the production of 
B-toxin, a small peptide encoded in the RNAIII 
transcript [19], and in another, extracts from the 
medicinal plant goldenseal (Hydrastis canaden-
sis) were found to inhibit RNAIII and a-toxin 
production, and reduce toxicity to human skin 
epithelial cells [20]. In both of the aforemen-
tioned studies, however, the specific compounds 
responsible for activity were not identified. 
Although quorum quenching in S. aureus has 
made substantial progress over the past decade, 
there remain many undevdoped areas that need 
to be addressed. AgrC receptor antagonists are 
the most advanced candidates, but the unde-
sirable pharmacokinetic properties of peptide 
inhibitors and the penchant for AgrC to evolve 
mutations raise questions about their long-term 
therapeutic utility [10]. AgrB is the most unique 
component of the agr system across Gram-pos-
itive pathogens [9], yet ambuic acid is the only 
reported AgrB inhibitor, and it has only lim-
ited efficacy [15]. In all S. aureus strains, AgrA 
is arguably the most conserved component of 
the system and is divergent from other classes 
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